{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:27:39Z","timestamp":1790245659538,"version":"4.1.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40264-025-01538-5","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T19:48:30Z","timestamp":1742413710000},"page":"719-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0202-8164","authenticated-orcid":false,"given":"Jonathan","family":"Renninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0844-1420","authenticated-orcid":false,"given":"Lisa","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-6682","authenticated-orcid":false,"given":"Heather","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"1538_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100575","volume":"32","author":"P Parsonidis","year":"2022","unstructured":"Parsonidis P, Papasotiriou I. Adoptive cellular transfer immunotherapies for cancer. Cancer Treat Res Commun. 2022;32: 100575. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100575.","journal-title":"Cancer Treat Res Commun."},{"key":"1538_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers15010094","volume":"15","author":"KK Fang","year":"2022","unstructured":"Fang KK, Lee JB, Zhang L. Adoptive cell therapy for t-cell malignancies. Cancers (Basel). 2022;15:94. https:\/\/doi.org\/10.3390\/cancers15010094.","journal-title":"Cancers (Basel)."},{"key":"1538_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724\u201340. https:\/\/doi.org\/10.1016\/j.cell.2017.01.016.","journal-title":"Cell"},{"key":"1538_CR4","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250. https:\/\/doi.org\/10.3389\/fimmu.2019.02250.","journal-title":"Front Immunol"},{"key":"1538_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2021.100360","volume":"21","author":"GB Kim","year":"2022","unstructured":"Kim GB, Riley JL, Levine BL. Engineering T cells to survive and thrive in the hostile tumor microenvironment. Curr Opin Biomed Eng. 2022;21:100360. https:\/\/doi.org\/10.1016\/j.cobme.2021.100360.","journal-title":"Curr Opin Biomed Eng."},{"key":"1538_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li D, Li X, Zhou W-L, Huang Y, Liang X, Jiang L, et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 2019;4:35. https:\/\/doi.org\/10.1038\/s41392-019-0070-9.","journal-title":"Signal Transduct Target Ther"},{"key":"1538_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21:449. https:\/\/doi.org\/10.1186\/s12967-023-04292-3.","journal-title":"J Transl Med"},{"key":"1538_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","volume":"18","author":"CR Maldini","year":"2018","unstructured":"Maldini CR, Ellis GI, Riley JL. CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol. 2018;18:605\u201316. https:\/\/doi.org\/10.1038\/s41577-018-0042-2.","journal-title":"Nat Rev Immunol"},{"key":"1538_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3955","volume":"42","author":"AME Abdalla","year":"2024","unstructured":"Abdalla AME, Miao Y, Ahmed AIM, Meng N, Ouyang C. CAR-T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives. Cell Biochem Funct. 2024;42: e3955. https:\/\/doi.org\/10.1002\/cbf.3955.","journal-title":"Cell Biochem Funct"},{"key":"1538_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16:97. https:\/\/doi.org\/10.1186\/s13045-023-01492-8.","journal-title":"J Hematol Oncol"},{"key":"1538_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181:46\u201362. https:\/\/doi.org\/10.1016\/j.cell.2020.03.001.","journal-title":"Cell"},{"key":"1538_CR12","doi-asserted-by":"publisher","first-page":"1202950","DOI":"10.3389\/fimmu.2023.1202950","volume":"14","author":"A Kent","year":"2023","unstructured":"Kent A, Crump LS, Davila E. Beyond \u03b1\u03b2 T cells: NK, iNKT, and \u03b3\u03b4T cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML. Front Immunol. 2023;14:1202950. https:\/\/doi.org\/10.3389\/fimmu.2023.1202950.","journal-title":"Front Immunol"},{"key":"1538_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa KY. CAR-T: what is next? Cancers (Basel). 2023;15:663. https:\/\/doi.org\/10.3390\/cancers15030663.","journal-title":"Cancers (Basel)."},{"key":"1538_CR14","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed: 30 Apr 2024."},{"key":"1538_CR15","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma. Accessed: 30 Apr 2024."},{"key":"1538_CR16","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma#:~:text=On%20May%2027%2C%202022%2C%20the,more%20lines%20of%20systemic%20therapy. Accessed: 30 Apr 2024."},{"key":"1538_CR17","unstructured":"Food and Drug Administration. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma#:~:text=On%20April%201%2C%202022%2C%20the,months%20of%20first%2Dline%20chemoimmunotherapy. Accessed: 30 Apr 2024."},{"key":"1538_CR18","unstructured":"Food and Drug Administration. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma. Accessed: 30 Apr 2024."},{"key":"1538_CR19","unstructured":"Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma. Accessed: 30 Apr 2024."},{"key":"1538_CR20","unstructured":"Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic. Accessed: 30 Apr 2024."},{"key":"1538_CR21","unstructured":"Food and Drug Administration. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma. Accessed: 30 Apr 2024."},{"key":"1538_CR22","unstructured":"Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma. Accessed: 30 Apr 2024."},{"key":"1538_CR23","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed: 30 Apr 2024.","DOI":"10.1158\/1078-0432.CCR-24-0378"},{"key":"1538_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7.","journal-title":"Lancet Oncol"},{"key":"1538_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005145","volume":"10","author":"X Qu","year":"2022","unstructured":"Qu X, An G, Sui W, Wang T, Zhang X, Yang J, et al. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. J Immunother Cancer. 2022;10: e005145. https:\/\/doi.org\/10.1136\/jitc-2022-005145.","journal-title":"J Immunother Cancer"},{"key":"1538_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022;97:537\u201347. https:\/\/doi.org\/10.1002\/ajh.26486.","journal-title":"Am J Hematol"},{"key":"1538_CR27","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.7150\/ijms.46811","volume":"18","author":"Q Yang","year":"2021","unstructured":"Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: a systematic review and meta-analysis. Int J Med Sci. 2021;18:1786\u201397. https:\/\/doi.org\/10.7150\/ijms.46811.","journal-title":"Int J Med Sci"},{"key":"1538_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28:735\u201342. https:\/\/doi.org\/10.1038\/s41591-022-01731-4.","journal-title":"Nat Med"},{"key":"1538_CR29","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315. https:\/\/doi.org\/10.1182\/blood.2022018893.","journal-title":"Blood"},{"key":"1538_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/nejmoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. New Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/nejmoa1709866.","journal-title":"New Engl J Med."},{"key":"1538_CR31","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614.","journal-title":"N Engl J Med"},{"key":"1538_CR32","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","volume":"41","author":"C Li","year":"2023","unstructured":"Li C, Wang D, Song Y, Huang H, Li J, Chen B, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1). J Clin Oncol. 2023;41:8025. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8025.","journal-title":"J Clin Oncol"},{"key":"1538_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/jco.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023;41:555\u201367. https:\/\/doi.org\/10.1200\/jco.21.02370.","journal-title":"J Clin Oncol"},{"key":"1538_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.21037\/tcr-22-344","volume":"11","author":"J Li","year":"2022","unstructured":"Li J, Tang Y, Huang Z. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials. Transl Cancer Res. 2022;11:569\u201379. https:\/\/doi.org\/10.21037\/tcr-22-344.","journal-title":"Transl Cancer Res."},{"key":"1538_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1538_CR36","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324. https:\/\/doi.org\/10.1182\/bloodadvances.2020003092.","journal-title":"Blood Adv"},{"key":"1538_CR37","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","volume":"134","author":"MC Pasquini","year":"2019","unstructured":"Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Ghobadi A, Komanduri KV, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood. 2019;134:764. https:\/\/doi.org\/10.1182\/blood-2019-124750.","journal-title":"Blood"},{"key":"1538_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/jco.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945\u201355. https:\/\/doi.org\/10.1200\/jco.20.03585.","journal-title":"J Clin Oncol"},{"key":"1538_CR39","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","volume":"7","author":"P Bader","year":"2023","unstructured":"Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, B\u00fccklein VL, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7:2436\u201348. https:\/\/doi.org\/10.1182\/bloodadvances.2022008981.","journal-title":"Blood Adv"},{"key":"1538_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102268","volume":"65","author":"V Barsan","year":"2023","unstructured":"Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023;65: 102268. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102268.","journal-title":"EClinicalMedicine."},{"key":"1538_CR41","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/jco.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805\u201315. https:\/\/doi.org\/10.1200\/jco.20.01467.","journal-title":"J Clin Oncol"},{"key":"1538_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9: eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700.","journal-title":"Sci Adv"},{"key":"1538_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003486","volume":"10","author":"E Donnadieu","year":"2022","unstructured":"Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. 2022;10: e003486. https:\/\/doi.org\/10.1136\/jitc-2021-003486.","journal-title":"J Immunother Cancer"},{"key":"1538_CR44","unstructured":"Food and Drug Administration. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous himeric antigen receptor (CAR) T cell immunotherapies 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Accessed: 30 Apr 2024."},{"key":"1538_CR45","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/jat.4100","volume":"41","author":"Y Jin","year":"2021","unstructured":"Jin Y, Dong Y, Zhang J, Sun J, Liu Y, Chen Y. The toxicity of cell therapy: mechanism, manifestations, and challenges. J Appl Toxicol. 2021;41:659\u201367. https:\/\/doi.org\/10.1002\/jat.4100.","journal-title":"J Appl Toxicol"},{"key":"1538_CR46","doi-asserted-by":"publisher","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030. https:\/\/doi.org\/10.3389\/fimmu.2023.1121030.","journal-title":"Front Immunol"},{"key":"1538_CR47","unstructured":"American Society of Hematology. T-cell malignancies represent small fraction of the reported secondary cancers following CAR-T in the FDA\u2019s Adverse Event Reporting System 2024. https:\/\/www.hematology.org\/newsroom\/press-releases\/2023\/t-cell-malignancies-represent-small-fraction-of-the-reported-secondary-cancers-following-car-t#:~:text=(WASHINGTON%2C%20March%2014%2C%202024,)%2C%20with%20T%2Dcell%20malignancies. Accessed: 26 Apr 2024."},{"key":"1538_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.36000\/HBT.OH.2024.19.138","volume":"19","author":"A M\u00fcller","year":"2024","unstructured":"M\u00fcller A. Rare adverse events of CAR T-cell therapy. Healthbook TIMES Onco Hema. 2024;19:42\u20139. https:\/\/doi.org\/10.36000\/HBT.OH.2024.19.138.","journal-title":"Healthbook TIMES Onco Hema"},{"key":"1538_CR49","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3390\/ijms22147652","volume":"22","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021;22:7652. https:\/\/doi.org\/10.3390\/ijms22147652.","journal-title":"Int J Mol Sci"},{"key":"1538_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z.","journal-title":"Nat Rev Cancer"},{"key":"1538_CR51","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146:940\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025.","journal-title":"J Allergy Clin Immunol"},{"key":"1538_CR52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","volume":"20","author":"CK Chou","year":"2020","unstructured":"Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020;20:653\u201364. https:\/\/doi.org\/10.1080\/14712598.2020.1729735.","journal-title":"Expert Opin Biol Ther"},{"key":"1538_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/itt.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019;8:43\u201352. https:\/\/doi.org\/10.2147\/itt.S202015.","journal-title":"Immunotargets Ther."},{"key":"1538_CR54","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25:e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1538_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56:552\u201366. https:\/\/doi.org\/10.1038\/s41409-020-01134-4.","journal-title":"Bone Marrow Transplant"},{"key":"1538_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"key":"1538_CR57","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.Cd-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1319.","journal-title":"Cancer Discov"},{"key":"1538_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez L, S\u00e1nchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3: e186. https:\/\/doi.org\/10.1097\/hs9.0000000000000186.","journal-title":"Hemasphere."},{"key":"1538_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8: e001511. https:\/\/doi.org\/10.1136\/jitc-2020-001511.","journal-title":"J Immunother Cancer"},{"key":"1538_CR60","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33:259\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003.","journal-title":"Ann Oncol"},{"key":"1538_CR61","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/tcrm.S223468","volume":"16","author":"S Si","year":"2020","unstructured":"Si S, Teachey DT. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;16:705\u201314. https:\/\/doi.org\/10.2147\/tcrm.S223468.","journal-title":"Ther Clin Risk Manag"},{"key":"1538_CR62","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","volume":"13","author":"SA Scott","year":"2023","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer J. 2023;13:191. https:\/\/doi.org\/10.1038\/s41408-023-00963-y.","journal-title":"Blood Cancer J"},{"key":"1538_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Front Immunol. 2021;12: 745320. https:\/\/doi.org\/10.3389\/fimmu.2021.745320.","journal-title":"Front Immunol"},{"key":"1538_CR64","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1016\/j.jtct.2023.12.261","volume":"30","author":"A Bajwa","year":"2024","unstructured":"Bajwa A, Zhao Q, Geer MJ, Mian A, Lin C, Frame D, et al. Efficacy of siltuximab for chimeric antigen receptor T-cell therapy toxicities\u2014a multicenter retrospective analysis. Transplant Cel Ther. 2024;30:S201\u20132. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.261.","journal-title":"Transplant Cel Ther."},{"key":"1538_CR65","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1182\/blood-2022-169809","volume":"140","author":"S Patel","year":"2022","unstructured":"Patel S, Cenin D, Corrigan D, Hamilton BK, Kalaycio M, Sobecks RM, et al. Siltuximab for first-line treatment of cytokine release syndrome: a response to the national shortage of tocilizumab. Blood. 2022;140:5073\u20134. https:\/\/doi.org\/10.1182\/blood-2022-169809.","journal-title":"Blood"},{"key":"1538_CR66","doi-asserted-by":"publisher","first-page":"2083479","DOI":"10.1080\/2162402x.2022.2083479","volume":"11","author":"G Leclercq","year":"2022","unstructured":"Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022;11:2083479. https:\/\/doi.org\/10.1080\/2162402x.2022.2083479.","journal-title":"Oncoimmunology."},{"key":"1538_CR67","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/jco.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of guideline immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO. J Clin Oncol. 2021;39:3978\u201392. https:\/\/doi.org\/10.1200\/jco.21.01992.","journal-title":"J Clin Oncol"},{"key":"1538_CR68","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"1538_CR69","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224\u20135. https:\/\/doi.org\/10.1126\/scitranslmed.3008226.","journal-title":"Sci Transl Med"},{"key":"1538_CR70","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.Cd-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664\u201379. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0040.","journal-title":"Cancer Discov"},{"key":"1538_CR71","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"key":"1538_CR72","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"1538_CR73","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"1538_CR74","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"key":"1538_CR75","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4. https:\/\/doi.org\/10.1186\/s40364-018-0116-0.","journal-title":"Biomark Res."},{"key":"1538_CR76","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.3390\/cells11244085","volume":"11","author":"L Huang","year":"2022","unstructured":"Huang L, Li J, Yang J, Zhang X, Zhang M, He J, et al. Safety and efficacy of humanized versus murinized CD19 and CD22 CAR T-cell cocktail therapy for refractory\/relapsed B-cell lymphoma. Cells. 2022;11:4085. https:\/\/doi.org\/10.3390\/cells11244085.","journal-title":"Cells"},{"key":"1538_CR77","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1007\/s00262-021-02941-4","volume":"70","author":"W Lu","year":"2021","unstructured":"Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer Immunol Immunother. 2021;70:3501\u201311. https:\/\/doi.org\/10.1007\/s00262-021-02941-4.","journal-title":"Cancer Immunol Immunother"},{"key":"1538_CR78","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"1538_CR79","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1158\/1078-0432.Ccr-19-1339","volume":"26","author":"G Heng","year":"2020","unstructured":"Heng G, Jia J, Li S, Fu G, Wang M, Qin D, et al. Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed\/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2020;26:1606\u201315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1339.","journal-title":"Clin Cancer Res"},{"key":"1538_CR80","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hon.2672","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma F, Ho JY, Du H, Xuan F, Wu X, Wang Q, et al. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematol Oncol. 2019;37:601\u20138. https:\/\/doi.org\/10.1002\/hon.2672.","journal-title":"Hematol Oncol"},{"key":"1538_CR81","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"key":"1538_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8: 355ra116. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621.","journal-title":"Sci Transl Med."},{"key":"1538_CR83","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116:9543\u201351. https:\/\/doi.org\/10.1073\/pnas.1819745116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1538_CR84","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado V, Rives S, Castell\u00e0 M, Alonso-Saladrigues A, Ben\u00edtez-Ribas D, Caballero-Ba\u00f1os M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies. Mol Ther. 2021;29:636\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.027.","journal-title":"Mol Ther"},{"key":"1538_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005701","volume":"11","author":"F Song","year":"2023","unstructured":"Song F, Hu Y, Zhang Y, Zhang M, Yang T, Wu W, et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J Immunother Cancer. 2023;11: e005701. https:\/\/doi.org\/10.1136\/jitc-2022-005701.","journal-title":"J Immunother Cancer"},{"key":"1538_CR86","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(14)61403-3.","journal-title":"Lancet"},{"key":"1538_CR87","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. https:\/\/doi.org\/10.1038\/mto.2016.11.","journal-title":"Mol Ther Oncolytics."},{"key":"1538_CR88","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang Y, Liu Y, Tong C, Wang C, Guo Y, et al. Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial. Leukemia. 2022;36:189\u201396. https:\/\/doi.org\/10.1038\/s41375-021-01345-8.","journal-title":"Leukemia"},{"key":"1538_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.564099","volume":"11","author":"X Zhou","year":"2020","unstructured":"Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, et al. Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. Front Immunol. 2020;11: 564099. https:\/\/doi.org\/10.3389\/fimmu.2020.564099.","journal-title":"Front Immunol"},{"key":"1538_CR90","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/jci126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129:2210\u201321. https:\/\/doi.org\/10.1172\/jci126397.","journal-title":"J Clin Invest"},{"key":"1538_CR91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J, Meng F, Cao Y, Zhang Y, Zhu X, Wang N, et al. Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J. 2021;11:131. https:\/\/doi.org\/10.1038\/s41408-021-00523-2.","journal-title":"Blood Cancer J"},{"key":"1538_CR92","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023;12:6124. https:\/\/doi.org\/10.3390\/jcm12196124.","journal-title":"J Clin Med"},{"key":"1538_CR93","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41409-021-01226-9","volume":"56","author":"M Shao","year":"2021","unstructured":"Shao M, Yu Q, Teng X, Guo X, Wei G, Xu H, et al. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I\/II clinical trial. Bone Marrow Transplant. 2021;56:1642\u201350. https:\/\/doi.org\/10.1038\/s41409-021-01226-9.","journal-title":"Bone Marrow Transplant"},{"key":"1538_CR94","doi-asserted-by":"publisher","first-page":"11063","DOI":"10.1111\/jcmm.17029","volume":"25","author":"F Hong","year":"2021","unstructured":"Hong F, Shi M, Cao J, Wang Y, Gong Y, Gao H, et al. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. J Cell Mol Med. 2021;25:11063\u201374. https:\/\/doi.org\/10.1111\/jcmm.17029.","journal-title":"J Cell Mol Med"},{"key":"1538_CR95","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564:273\u20137. https:\/\/doi.org\/10.1038\/s41586-018-0774-y.","journal-title":"Nature"},{"key":"1538_CR96","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al. Lymphodepletion\u2014an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935.","journal-title":"Front Immunol"},{"key":"1538_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611366","volume":"12","author":"Z Yan","year":"2021","unstructured":"Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021;12: 611366. https:\/\/doi.org\/10.3389\/fimmu.2021.611366.","journal-title":"Front Immunol"},{"key":"1538_CR98","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, et al. Role of Fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25:1092\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.008.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1538_CR99","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1148\/radiol.2021210760","volume":"302","author":"DA Smith","year":"2022","unstructured":"Smith DA, Kikano E, Tirumani SH, de Lima M, Caimi P, Ramaiya NH. Imaging-based toxicity and response pattern assessment following CAR T-cell therapy. Radiology. 2022;302:438\u201345. https:\/\/doi.org\/10.1148\/radiol.2021210760.","journal-title":"Radiology"},{"key":"1538_CR100","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/cancers16142585","volume":"16","author":"C Pozzessere","year":"2024","unstructured":"Pozzessere C, Mazini B, Omoumi P, Jreige M, Noirez L, Digklia A, et al. Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: a comprehensive imaging-based review. Cancers (Basel). 2024;16:2585. https:\/\/doi.org\/10.3390\/cancers16142585.","journal-title":"Cancers (Basel)."},{"key":"1538_CR101","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.Ccr-21-0470","volume":"27","author":"AJ Van De Vyver","year":"2021","unstructured":"Van De Vyver AJ, Marrer-Berger E, Wang K, Lehr T, Walz AC. Cytokine release syndrome by T-cell-redirecting therapies: can we predict and modulate patient risk? Clin Cancer Res. 2021;27:6083\u201394. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0470.","journal-title":"Clin Cancer Res"},{"key":"1538_CR102","doi-asserted-by":"publisher","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco R, Mussetti A, Villagr\u00e1n-Garc\u00eda M, Sureda A. CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern? Front Neurol. 2023;14:1144414. https:\/\/doi.org\/10.3389\/fneur.2023.1144414.","journal-title":"Front Neurol"},{"key":"1538_CR103","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111:646\u201354. https:\/\/doi.org\/10.1093\/jnci\/djz017.","journal-title":"J Natl Cancer Inst"},{"key":"1538_CR104","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/ppo.0000000000000507","volume":"27","author":"H Danish","year":"2021","unstructured":"Danish H, Santomasso BD. Neurotoxicity biology and management. Cancer J. 2021;27:126\u201333. https:\/\/doi.org\/10.1097\/ppo.0000000000000507.","journal-title":"Cancer J"},{"key":"1538_CR105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"1538_CR106","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40:367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"1538_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis. 2022;14: e1576. https:\/\/doi.org\/10.1002\/wsbm.1576.","journal-title":"WIREs Mech Dis."},{"key":"1538_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 2020;11: 577027. https:\/\/doi.org\/10.3389\/fimmu.2020.577027.","journal-title":"Front Immunol"},{"key":"1538_CR109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of immunotherapy-related toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020.","journal-title":"J Natl Compr Canc Netw"},{"key":"1538_CR110","doi-asserted-by":"publisher","first-page":"1108297","DOI":"10.3389\/fneur.2023.1108297","volume":"14","author":"V Genoud","year":"2023","unstructured":"Genoud V, Migliorini D. Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Front Neurol. 2023;14:1108297. https:\/\/doi.org\/10.3389\/fneur.2023.1108297.","journal-title":"Front Neurol"},{"key":"1538_CR111","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141:2430\u201342. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"key":"1538_CR112","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29:1710\u20137. https:\/\/doi.org\/10.1038\/s41591-023-02404-6.","journal-title":"Nat Med"},{"key":"1538_CR113","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2022.w30186","volume":"152","author":"S Stolz","year":"2022","unstructured":"Stolz S, Roncador M, R\u00f6sler W, Zenz T, Manz MG, M\u00fcller AMS, et al. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. Swiss Med Wkly. 2022;152: w30186. https:\/\/doi.org\/10.4414\/smw.2022.w30186.","journal-title":"Swiss Med Wkly"},{"key":"1538_CR114","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022;28:294\u2013302. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.006.","journal-title":"Transplant Cell Ther."},{"key":"1538_CR115","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","volume":"24","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Martin S, Yates B, Wolters PL, Kaplan C, Smith H, et al. Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies. Neuro Oncol. 2022;24:1584\u201397. https:\/\/doi.org\/10.1093\/neuonc\/noac034.","journal-title":"Neuro Oncol"},{"key":"1538_CR116","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/jci85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123\u201338. https:\/\/doi.org\/10.1172\/jci85309.","journal-title":"J Clin Invest"},{"key":"1538_CR117","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/jco.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38:3095\u2013106. https:\/\/doi.org\/10.1200\/jco.19.02103.","journal-title":"J Clin Oncol"},{"key":"1538_CR118","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2159-8290.Cd-17-1084","volume":"7","author":"CL Mackall","year":"2017","unstructured":"Mackall CL, Miklos DB. CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity. Cancer Discov. 2017;7:1371\u20133. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1084.","journal-title":"Cancer Discov"},{"key":"1538_CR119","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","volume":"11","author":"EL Siegler","year":"2020","unstructured":"Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor t cell therapy: insights into mechanisms and novel therapies. Front Immunol. 2020;11:1973. https:\/\/doi.org\/10.3389\/fimmu.2020.01973.","journal-title":"Front Immunol"},{"key":"1538_CR120","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0698.","journal-title":"Cancer Discov"},{"key":"1538_CR121","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77:1536\u201342. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2703.","journal-title":"JAMA Neurol"},{"key":"1538_CR122","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212\u201321. https:\/\/doi.org\/10.1182\/blood-2018-12-893396.","journal-title":"Blood"},{"key":"1538_CR123","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s10072-023-06841-6","volume":"44","author":"L Fontanelli","year":"2023","unstructured":"Fontanelli L, Pizzanelli C, Milano C, Cassano Cassano R, Galimberti S, Rossini MI, et al. Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series. Neurol Sci. 2023;44:3291\u20137. https:\/\/doi.org\/10.1007\/s10072-023-06841-6.","journal-title":"Neurol Sci"},{"key":"1538_CR124","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00415-023-11595-4","volume":"270","author":"U Pensato","year":"2023","unstructured":"Pensato U, Amore G, Muccioli L, Sammali S, Rondelli F, Rinaldi R, et al. CAR t-cell therapy in Bologna-Neurotoxicity Treatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study. J Neurol. 2023;270:2659\u201373. https:\/\/doi.org\/10.1007\/s00415-023-11595-4.","journal-title":"J Neurol"},{"key":"1538_CR125","doi-asserted-by":"publisher","first-page":"1110647","DOI":"10.3389\/fneur.2023.1110647","volume":"14","author":"OH Butt","year":"2023","unstructured":"Butt OH, Zhou AY, Ances BM, DiPersio JF, Ghobadi A. A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Front Neurol. 2023;14:1110647. https:\/\/doi.org\/10.3389\/fneur.2023.1110647.","journal-title":"Front Neurol"},{"key":"1538_CR126","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.1212\/WNL.0000000000206540","volume":"102","author":"E Nie","year":"2024","unstructured":"Nie E, Su Y-J, Baird J, Agarwal N, Bharadwaj S, Weng W-K, et al. Clinical and neuroradiological features of immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy in mantle cell lymphoma (MCL) (S23.007). Neurology. 2024;102:6545. https:\/\/doi.org\/10.1212\/WNL.0000000000206540.","journal-title":"Neurology"},{"key":"1538_CR127","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5:2799\u2013806. https:\/\/doi.org\/10.1182\/bloodadvances.2021004575.","journal-title":"Blood Adv"},{"key":"1538_CR128","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5:3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"key":"1538_CR129","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.3390\/cancers15225443","volume":"15","author":"JW de Boer","year":"2023","unstructured":"de Boer JW, Keijzer K, Pennings ERA, van Doesum JA, Spanjaart AM, Jak M, et al. Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities. Cancers (Basel). 2023;15:5443. https:\/\/doi.org\/10.3390\/cancers15225443.","journal-title":"Cancers (Basel)."},{"key":"1538_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005459","volume":"10","author":"Y Amidi","year":"2022","unstructured":"Amidi Y, Eckhardt CA, Quadri SA, Malik P, Firme MS, Jones DK, et al. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. J Immunother Cancer. 2022;10: e005459. https:\/\/doi.org\/10.1136\/jitc-2022-005459.","journal-title":"J Immunother Cancer"},{"key":"1538_CR131","doi-asserted-by":"publisher","first-page":"s193","DOI":"10.1016\/j.jtct.2023.12.251","volume":"30","author":"JJ Huang","year":"2024","unstructured":"Huang JJ, Liang EC, Albittar A, Portuguese AJ, Wuliji N, Torkelson A, et al. Early prediction of severe ICANS after CD19 CAR T-cell therapy based on serum ferritin levels. Transplant Cell Ther. 2024;30:s193\u20134. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.251.","journal-title":"Transplant Cell Ther"},{"key":"1538_CR132","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jha2.350","volume":"3","author":"A Taneja","year":"2022","unstructured":"Taneja A, Jain T. CAR-T-OPENIA: chimeric antigen receptor T-cell therapy-associated cytopenias. EJHaem. 2022;3:32\u20138. https:\/\/doi.org\/10.1002\/jha2.350.","journal-title":"EJHaem."},{"key":"1538_CR133","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460\u20139. https:\/\/doi.org\/10.1182\/blood.2022017415.","journal-title":"Blood"},{"key":"1538_CR134","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6:6109\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2022008320.","journal-title":"Blood Adv"},{"key":"1538_CR135","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/cancers14061501","volume":"14","author":"N Sharma","year":"2022","unstructured":"Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-t cell therapy\u2014a brief review of a complex problem. Cancers (Basel). 2022;14:1501. https:\/\/doi.org\/10.3390\/cancers14061501.","journal-title":"Cancers (Basel)."},{"key":"1538_CR136","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/s1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"key":"1538_CR137","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776\u201387. https:\/\/doi.org\/10.1182\/bloodadvances.2020002509.","journal-title":"Blood Adv"},{"key":"1538_CR138","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","volume":"54","author":"Y Xia","year":"2022","unstructured":"Xia Y, Zhang J, Li J, Zhang L, Li J, Fan L, et al. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Ann Med. 2022;54:2951\u201365. https:\/\/doi.org\/10.1080\/07853890.2022.2136748.","journal-title":"Ann Med"},{"key":"1538_CR139","doi-asserted-by":"publisher","first-page":"204993612110367","DOI":"10.1177\/20499361211036773","volume":"8","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis. 2021;8:20499361211036772. https:\/\/doi.org\/10.1177\/20499361211036773.","journal-title":"Ther Adv Infect Dis."},{"key":"1538_CR140","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","volume":"27","author":"R Chakraborty","year":"2021","unstructured":"Chakraborty R, Hill BT, Majeed A, Majhail NS. Late Effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transplant Cell Ther. 2021;27:222\u20139. https:\/\/doi.org\/10.1016\/j.jtct.2020.10.002.","journal-title":"Transplant Cell Ther."},{"key":"1538_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997589","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, Zhang Y, Shan M, Zong X, Geng H, Li J, et al. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. Front Immunol. 2022;13: 997589. https:\/\/doi.org\/10.3389\/fimmu.2022.997589.","journal-title":"Front Immunol"},{"key":"1538_CR142","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006406","volume":"11","author":"O Penack","year":"2023","unstructured":"Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, et al. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023;11: e006406. https:\/\/doi.org\/10.1136\/jitc-2022-006406.","journal-title":"J Immunother Cancer"},{"key":"1538_CR143","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643\u201350. https:\/\/doi.org\/10.1038\/s41409-019-0487-3.","journal-title":"Bone Marrow Transplant"},{"key":"1538_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.702644","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang L, Hong R, Zhou L, Ni F, Zhang M, Zhao H, et al. New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia. Front Oncol. 2021;11: 702644. https:\/\/doi.org\/10.3389\/fonc.2021.702644.","journal-title":"Front Oncol"},{"key":"1538_CR145","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3892\/ol.2023.13924","volume":"26","author":"T Qiu","year":"2023","unstructured":"Qiu T, Hu L, Zhang Y, Wang Y, Ma S, Li D, et al. Cytopenia after CAR-T cell therapy: analysis of 63 patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Oncol Lett. 2023;26:338. https:\/\/doi.org\/10.3892\/ol.2023.13924.","journal-title":"Oncol Lett"},{"key":"1538_CR146","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138:2499\u2013513. https:\/\/doi.org\/10.1182\/blood.2020010543.","journal-title":"Blood"},{"key":"1538_CR147","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88. https:\/\/doi.org\/10.1186\/s13045-023-01465-x.","journal-title":"J Hematol Oncol"},{"key":"1538_CR148","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","volume":"62","author":"T Wittmann Dayagi","year":"2021","unstructured":"Wittmann Dayagi T, Sherman G, Bielorai B, Adam E, Besser MJ, Shimoni A, et al. Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leuk Lymphoma. 2021;62:1692\u2013701. https:\/\/doi.org\/10.1080\/10428194.2021.1881506.","journal-title":"Leuk Lymphoma"},{"key":"1538_CR149","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","volume":"10","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, Flynn JR, Devlin SM, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020;10:79. https:\/\/doi.org\/10.1038\/s41408-020-00346-7.","journal-title":"Blood Cancer J"},{"key":"1538_CR150","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018;67:533\u201340. https:\/\/doi.org\/10.1093\/cid\/ciy152.","journal-title":"Clin Infect Dis"},{"key":"1538_CR151","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00277-023-05131-7","volume":"102","author":"S Mercadal","year":"2023","unstructured":"Mercadal S, Gomez CA, Lee CJ, Couriel DR. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. Ann Hematol. 2023;102:1837\u201343. https:\/\/doi.org\/10.1007\/s00277-023-05131-7.","journal-title":"Ann Hematol"},{"key":"1538_CR152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26:26\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.003.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1538_CR153","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","volume":"5","author":"JH Baird","year":"2021","unstructured":"Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021;5:143\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2020002732.","journal-title":"Blood Adv"},{"key":"1538_CR154","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136:925\u201335. https:\/\/doi.org\/10.1182\/blood.2019004000.","journal-title":"Blood"},{"key":"1538_CR155","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1080\/10428194.2023.2220455","volume":"64","author":"M McGann","year":"2023","unstructured":"McGann M, Velayati A, Roubal K, Granger K, Davis JA, Gaffney KJ, et al. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies. Leuk Lymphoma. 2023;64:1592\u20135. https:\/\/doi.org\/10.1080\/10428194.2023.2220455.","journal-title":"Leuk Lymphoma"},{"key":"1538_CR156","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2022;57:1477\u201388. https:\/\/doi.org\/10.1038\/s41409-022-01756-w.","journal-title":"Bone Marrow Transplant"},{"key":"1538_CR157","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","volume":"49","author":"I Los-Arcos","year":"2021","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49:215\u201331. https:\/\/doi.org\/10.1007\/s15010-020-01521-5.","journal-title":"Infection"},{"key":"1538_CR158","doi-asserted-by":"publisher","first-page":"153","DOI":"10.56875\/2589-0646.1049","volume":"15","author":"A Haroon","year":"2022","unstructured":"Haroon A, Muhsen IN, Abid MB, Albabtain A, Alahmari A, Ahmed SO, et al. Infectious complications and preventative strategies following chimeric antigen receptor T-cells (CAR-T cells) therapy for B-cell malignancies. Hematol Oncol Stem Cell Ther. 2022;15:153\u20138. https:\/\/doi.org\/10.56875\/2589-0646.1049.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1538_CR159","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Li\u00e9vin","year":"2022","unstructured":"Li\u00e9vin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant. 2022;57:431\u20139. https:\/\/doi.org\/10.1038\/s41409-021-01526-0.","journal-title":"Bone Marrow Transplant"},{"key":"1538_CR160","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","volume":"27","author":"J Meir","year":"2021","unstructured":"Meir J, Abid MA, Abid MB. State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses. Transplant Cell Ther. 2021;27:973\u201387. https:\/\/doi.org\/10.1016\/j.jtct.2021.09.016.","journal-title":"Transplant Cell Ther."},{"key":"1538_CR161","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","volume":"35","author":"K Perica","year":"2021","unstructured":"Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021;35:3268\u201371. https:\/\/doi.org\/10.1038\/s41375-021-01196-3.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"1538_CR162","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14157","volume":"25","author":"E Kampouri","year":"2023","unstructured":"Kampouri E, Little JS, Rejeski K, Manuel O, Hammond SP, Hill JA. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis. 2023;25(Suppl 1): e14157. https:\/\/doi.org\/10.1111\/tid.14157.","journal-title":"Transpl Infect Dis"},{"key":"1538_CR163","doi-asserted-by":"publisher","first-page":"9228","DOI":"10.1002\/cam4.5665","volume":"12","author":"MZ Powell","year":"2023","unstructured":"Powell MZ, Mara KC, Bansal R, Hathcock MA, Khurana A, Bennani NN, et al. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients. Cancer Med. 2023;12:9228\u201335. https:\/\/doi.org\/10.1002\/cam4.5665.","journal-title":"Cancer Med"},{"key":"1538_CR164","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000858","volume":"7","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, et al. Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL. Hemasphere. 2023;7: e858. https:\/\/doi.org\/10.1097\/hs9.0000000000000858.","journal-title":"Hemasphere."},{"key":"1538_CR165","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo H, Wang N, Huang L, Zhou X, Jin J, Li C, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer. 2019;7:271. https:\/\/doi.org\/10.1186\/s40425-019-0767-x.","journal-title":"J Immunother Cancer"},{"key":"1538_CR166","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","volume":"4","author":"C Diorio","year":"2020","unstructured":"Diorio C, Shaw PA, Pequignot E, Orlenko A, Chen F, Aplenc R, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Adv. 2020;4:5174\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2020002592.","journal-title":"Blood Adv"},{"key":"1538_CR167","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390:584\u20136. https:\/\/doi.org\/10.1056\/NEJMp2400209.","journal-title":"N Engl J Med"},{"key":"1538_CR168","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02826-w.","journal-title":"Nat Med"},{"key":"1538_CR169","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/jama.2024.1011","volume":"331","author":"M Suran","year":"2024","unstructured":"Suran M. FDA adds boxed warning to CAR T-cell therapies, but says benefits outweigh risks of secondary cancers. JAMA. 2024;331:818\u201320. https:\/\/doi.org\/10.1001\/jama.2024.1011.","journal-title":"JAMA"},{"key":"1538_CR170","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30:338\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02767-w.","journal-title":"Nat Med"},{"key":"1538_CR171","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187. https:\/\/doi.org\/10.1155\/2018\/2386187.","journal-title":"J Immunol Res"},{"key":"1538_CR172","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CHJ Lamers","year":"2013","unstructured":"Lamers CHJ, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of Metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21:904\u201312. https:\/\/doi.org\/10.1038\/mt.2013.17.","journal-title":"Mol Ther"},{"key":"1538_CR173","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"key":"1538_CR174","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu Y, Guo Y, Wu Z, Feng K, Tong C, Wang Y, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy. 2020;22:573\u201380. https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.088.","journal-title":"Cytotherapy"},{"key":"1538_CR175","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66:1425\u201336. https:\/\/doi.org\/10.1007\/s00262-017-2034-7.","journal-title":"Cancer Immunol Immunother"},{"key":"1538_CR176","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","volume":"10","author":"KC Feng","year":"2017","unstructured":"Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:4. https:\/\/doi.org\/10.1186\/s13045-016-0378-7.","journal-title":"J Hematol Oncol"},{"key":"1538_CR177","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","volume":"24","author":"Y Guo","year":"2018","unstructured":"Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018;24:1277\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0432.","journal-title":"Clin Cancer Res"},{"key":"1538_CR178","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as Potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183:126-42.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022.","journal-title":"Cell"},{"key":"1538_CR179","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u2013103. https:\/\/doi.org\/10.1038\/s41591-021-01564-7.","journal-title":"Nat Med"},{"key":"1538_CR180","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1538_CR181","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","volume":"72","author":"A Shimabukuro-Vornhagen","year":"2022","unstructured":"Shimabukuro-Vornhagen A, B\u00f6ll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, et al. Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin. 2022;72:78\u201393. https:\/\/doi.org\/10.3322\/caac.21702.","journal-title":"CA Cancer J Clin"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01538-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01538-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01538-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:55:02Z","timestamp":1750150502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01538-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":181,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01538-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"18 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work and the related publication were sponsored by GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of GSK. J.R. and H.S. hold financial equities in GSK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable; no data were analyzed in this opinion paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the concept of this manuscript, and all authors reviewed the manuscript and provided final approval for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}}]}}